Gadofosveset (EPIX/Schering)

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 967-976

  Farooki, Aamer ^a   Narra, Vamsidhar ^a   Brown, J Brown ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOFOSVESET; GADOLINIUM; ORGANOMETALLIC COMPOUND;

ANIMAL; CAPILLARY PERMEABILITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; INFLAMMATION; NEOPLASM; PATHOLOGY; REVIEW; VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CONTRAST MEDIA; GADOLINIUM; HUMANS; INFLAMMATION; NEOPLASMS; ORGANOMETALLIC COMPOUNDS;

EID: 16644389388     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. 126390 Tolerance of extracellular contrast agents for magnetic resonance imaging. Weinmann HJ, Press WR, Gries H INVEST RADIOL 1990 25 49-50
2. 211725 Metasyn signs $12 million partnership with Daiichi Radioisotope of Japan. Metasyn Inc PRESS RELEASE 1996 April 09
3. 216453 New patent developments. SCRIP 1996 2129 26
4. 220569 Mallinckrodt, Metasyn form strategic alliance. Mallinckrodt Group Inc PRESS RELEASE 1996 September 30
5. 264421 EPIX Medical and Mallinckrodt begin phase II clinical trial of MRI vascular contrast agent for cardiology indications. EPIX Medical Inc PRESS RELEASE 1997 September 29
6. 280973 Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB INVEST RADIOL 1997 32 12 741-747
7. 281050 EPIX Medical and Mallinckrodt announce completion of enrollment for phase II clinical trial of MS-325. EPIX Medical Inc PRESS RELEASE 1998 March 12
8. 281962 EPIX Medical and Mallinckrodt announce completion of MS-325 phase I dose escalation study - increased dose level administered to patients in phase II feasibility trial for cardiac indication. EPIX Medical Inc PRESS RELEASE 1998 March 23
9. 291913 EPIX Medical and Mallinckrodt announce results from phase II clinical trial for MS-325 magnetic resonance contrast agent; agent demonstrates 82% accuracy for identifying clinically significant stenosis. EPIX Medical Inc PRESS RELEASE 1998 July 16
10. 301058 Three-dimensional MRI of coronary arteries using an intravascular contrast agent. Li D, Dolan RP, Walovitch RC, Lauffer RB MAGN RESON MED 1998 39 6 1014-1018
11. 301059 Steady-state and dynamic MR angiography with MS-325: Initial experience in humans. Grist TM, Korosec FR, Peters DC, Witte S, Walovitch RC, Dolan RP, Bridson WE, Yucel EK, Mistretta CA RADIOL 1998 207 2 539-544
12. 301060 MS-325: Albumin-targeted contrast agent for MR angiography. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC RADIOL 1998 207 2 529-538
13. 301065 MS-325: A small-molecule vascular imaging agent for magnetic resonance imaging. Lauffer RB, Parmelee DJ, Ouellet HS, Dolan RP, Sajiki H, Scott DM, Bernard PJ, Buchanan EM, Ong KY, Tyeklar Z, Midelfort KS et al ACAD RADIOL 1996 3 Suppl 2 S356-S358
14. 341072 Siemens Medical Systems, EPIX Medical, Mallinckrodt collaborate on magnetic resonance imaging system. EPIX Medical Inc PRESS RELEASE 1999 September 21
15. 360974 AngioMARK shows promise in mouse model for MD. EPIX Medical Inc PRESS RELEASE 2000 March 27
16. 370518 Schering signs MS-325 agreements with EPIX and Mallinckrodt. Schering AG, EPIX Medical Inc, Mallinckrodt Inc PRESS RELEASE 2000 June 09
17. 378636 Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography. Stuber M, Botnar RM, Danias PG, McConnell MV, Kissinger KV, Yucel EK, Manning WJ J MAGN RESON IMAGING 1999 10 5 790-799
18. 378642 Blood pool contrast agents for cardiovascular MR imaging. Kroft LJ, de Roos A J MAGN RESON IMAGING 1999 10 3 395-403
19. 390703 Vessel wall enhancement with MS-325 facilitates plaque detection and characterization. CIRCULATION 2000 102 18 Suppl Abs 1832
20. 395608 Schering acquires Japanese rights to EPIX's MS-325. Schering AG PRESS RELEASE 2001 January 09
21. 404289 MS-325: EPIX's lead product in development. EPIX Medical Inc COMPANY WORLD WIDE WEB SITE 2001 April 05
22. 423461 EPIX Medical's MS-325 sees its horizons broaden. EPIX Medical Inc PRESS RELEASE 2001 September 27
23. 443920 Positive phase III MS-325 results reported at ACC. EPIX Medical Inc PRESS RELEASE 2002 March 18
24. 461241 The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. McMurry TJ, Parmelee DJ, Sajiki H, Scott DM, Ouellet HS, Walovitch RC, Tyeklar Z, Dumas S, Bernard P, Nadler S, Midelfort K et al J MED CHEM 2002 45 16 3465-3474
25. 472552 Results of a multicenter phase III trial of magnetic resonance angiography (MRA) with MS-325 for the detection of peripheral vascular disease in the aortoiliac region. Wolff S, MS-325-12 Trial Investigators CIRCULATION 2002 106 19 Abs 3408
26. 481485 Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Adzamli K, Yablonskiy DA, Chicoine MR, Won EK, Galen KP, Zahner MC, Woolsey TA, Ackerman JJ MAGN RESON MED 2003 49 3 586-590
27. 481490 Interstitial MR lymphography with MS-325: Characterization of normal and tumor-invaded lymph nodes in a rabbit model. Herborn CU, Lauenstein TC, Vogt FM, Lauffer RB, Debatin JF, Ruehm SG AM J ROENTGENOL 2002 179 6 1567-1572
28. 496032 Tissue-specific MR contrast agents. Weinmann HJ, Ebert W, Misselwitz B, Schmitt W EUR J RADIOL 2003 46 1 33-44
29. 496607 MS-325 completes phase III vascular imaging studies. EPIX Medical Inc PRESS RELEASE 2003 July 10
30. 505572 The anti-tumor somatostatin analogue TT-232 induces cell cycle arrest through PKCδ and c-Src. Stetak A, Lankenau A, Vantus T, Csermely P, Ullrich A, Keri G BIOCHEM BIOPHYS RES COMMUN 2001 285 2 483-488
31. 512320 EPIX releases MS-325 safety data for renally-impaired patients. EPIX Medical Inc PRESS RELEASE 2003 November 10
32. 513858 Relative performance of attenuation-corrected and uncorrected ECG-Gated SPECT myocardial perfusion imaging in relation to body mass index. Bateman TM, Heller GV, Johnson LL, Case JA, Cullom JS, Moutray KL, Garcia EV CIRCULATION 2003 108 17 Abs 2093
33. 516107 MRI of blood volume with MS 325 in experimental choroidal melanoma. Krause MHJ, Kwong KK, Xiong J, Gragoudas ES, Young LHY MAGN RESON IMAGING 2003 21 7 725-732
34. 516108 Magnetic resonance imaging of myocardial contrast enhancement with MS-325 and its relation to myocardial blood flow and the perfusion reserve. Jerosch-Herold M, Hu X, Murthy NS, Rickers C, Stillman AE J MAGN RESON IMAGING 2003 18 5 544-554
35. 516111 Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Corot C, Violas X, Robert P, Gagneur G, Port M INVEST RADIOL 2003 38 6 311-319
36. 517262 EPIX Submits MS-325 new drug application to FDA. EPIX Medical Inc PRESS RELEASE 2003 December 16
37. 519034 EPIX granted patent for MS-325 composition of matter. EPIX Medical Inc PRESS RELEASE 2004 January 13
38. 526180 The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. Caravan P, Cloutier NL, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC Jr, Looby RJ, Supkowski RM, Horrocks WD Jr, McMurry TJ, Lauffer RB J AM CHEM SOC 2002 124 12 3152-3162
39. 526192 Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: And experimental study in rats. Schmiedl U, Ogan MD, Moseley ME, Brasch RC AM J ROENTGENOL 1986 147 6 1263-1270
40. 526193 Carotid MR angiography: Phase II study of safety and efficacy for MS-325. Bluemke DA, Stillman AE, Bis KG, Grist TM, Baum RA, D'Agostino R, Malden ES, Pierro JA, Yucel EK RADIOLOGY ONCOL 2001 219 1 114-122
41. 526278 Coronary arteries: Breath-hold, gadolinium-enhanced, three-dimensional MR angiography. Goldfarb JW, Edelman RR RADIOLOGY ONCOL 1998 206 3 830-834
42. 526279 MRI detection of myocardial perfusion defects due to coronary artery stenosis with MS-325. Kraitchman DL, Chin BB, Heldman AW, Solaiyappan M, Bluemke DA J MAGN RESON IMAGING 2002 15 2 149-158
43. 526280 MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC J MAGN RESON IMAGING 2001 14 3 237-242
44. 526281 Interstitial MR lymphography with iron oxide particles: Results in tumor-free and VX2 tumor-bearing rabbits. Taupitz M, Wagner S, Hamm B, Binder A, Pfefferer D AM J ROENTGENOL 1993 161 1 193-200
45. 526282 Elevated levels of albumin in soleus and diaphragm muscles of mdx mice. Dupont-Versteegden EE, Kitten AM, Katz MS, McCarter RJ PROC SOC EXP BIOL MED 1996 213 3 281-286
46. 526283 Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy. Straub V, Donahue KM, Allamand V, Davisson RL, Kim YR, Campbell KP MAGN RESON MED 2000 44 4 655-659
47. 526284 Contrast-enhanced magnetic resonance imaging (MS-325) in a murine model of systemic lupus erythematosus. Herborn CU, Waldschuetz R, Lauenstein TC, Goyen M, Lauffer RB, Moeroey T, Debatin JF, Ruehm SG INVEST RADIOL 2002 37 8 464-469
48. 526954 Epix Medical Inc - Form 10K filed on 8 March 2004. EPIX Medical Inc FORM 10-K 2004 March 08
49. 540642 MR angiography with gadofosveset trisodium for peripheral vascular disease: Phase II trial. Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, Mohler ER, 3rd RADIOL 2003 229 3 811-820
50. 542710 Schering submits MS-325 for magnetic resonance angiography marketing approval in the EU. EPIX Medical Inc PRESS RELEASE 2004 June 07
51. 549546 Magnetic resonance angiography of the peripheral arteries: Current status. Meaney JF EUR RADIOL 2003 13 4 836-852
52. 549547 Contrast-enhanced MR angiography. Maki JH, Chenevert TL, Prince MR ABDOMINAL IMAGING 1998 23 5 469-484
53. 549561 MR angiography of intracranial aneurysms: A comparison of 0.5 T and 1.5 T. Korogi Y, Takahashi M, Mabuchi N, Watabe T, Shiokawa Y, Shiga H, O'Uchi T, Nakagawa T, Miki H, Horikawa Y, Fujiwara S, Furuse M COMPUT MED IMAGING GRAPH 1997 21 2 111-116
54. 549563 Contrast-enhanced peripheral MR angiography at 3.0 Tesla: Initial experience with a whole-body scanner in healthy volunteers. Leiner T, de Vries M, Hoogeveen R, Vasbinder GB, Lemaire E, van Engelshoven JM J MAGN RESON IMAGING 2003 17 5 609-614
55. 552087 Drug development pipeline: Gadofosveset. EPIX Medical Inc COMPANY COMMUNICATION 2004 August 03
56. 552805 Myocardial viability: Rapid assessment with delayed contrast-enhanced MR imaging with three-dimensional inversion-recovery prepared pulse sequence. Kuhl HP, Papavasiliu TS, Beek AM, Hofman MB, Heusen NS, van Rossum AC RADIOL 2004 230 2 572-586